Heparin Binding Assay of von Willebrand Factor (vWF) in Plasma Milieu – Evidence of the Importance of the Multimerization Degree of vWF

Summary

We developed a simple and fast method for studying the heparin binding of von Willebrand factor (vWF) in the plasma milieu. Using plasma from patients with von Willebrand disease (vWD) subtype II, we found that the heparin binding was impaired when compared with a normal plasma control. Further experiments performed with purified vWF of various multimeric composition, obtained either by gradual reduction or gel filtration, confirmed that heparin binding is dependent on the multimerization of vWF and that high molecular weight (HMW) multimers of vWF are required for normal heparin binding. After reduction of plasma vWF by 1.5 mM DTT, the vWF monomer still binds to heparin but to a lower extent. Under these conditions, no significant differences were obtained between control and patients showing that the heparin binding domain located on the vWF subunit is not altered in the subtypes IIA, IIB and IIC studied.

• References

• 1 Moroose R, Hoyer LW. Von Willebrand factor and platelet function. Annu Rev Med 1986; 37: 157-163
• 2 Badimon L, Badimon JJ, Rand J, Turitto VT, Fuster V. Platelet deposition on von Willebrand factor deficient vessel. Extracorporel perfusion studies in saline with von Willebrand’s disease using native and heparinized blood. J Lab Clin Med 1987; 110: 634-647
• 3 Girma JP, Kalafatis M, Pietu G, Lavergne JM, Chopek MW, Edgington TS, Meyer D. Mapping of distinct von Willebrand factor domains interacting with platelet GPIb and GPIIb IIIa and with collagen using monoclonal antibodies. Blood 1986; 67: 1356-1366
• 4 Fujimura Y, Titani K, Holland LZ, Roberts JR, Kostel P, Ruggeri ZM, Zimmerman TS. A heparin binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from aminoacid residue Val 449 to Lys 728. J Biol Chem 1987; 4: 1734-1739
• 5 Madalas F, Bell WR, Castaldi PA. Isolation and insolubilisation of human FVIII by affinity chromatography. Haemostasis 1978; 7: 321-331
• 6 Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, Mc Kee PA. Structure of human von Willebrand factor. J Clin Invest 1985; 76: 1491-1500
• 7 Andrews RK, Gorman JJ, Booth WJ, Corino GL, Castaldi PA, Berndt MC. Cross linking of a monomeric 39/34 kDa dispase fragment of von Willebrand factor (Leu-480/Val 481 – Gly 718) to the N terminal region of the chain of membrane glycoprotein Ib on intact platelet with bis (sulfosuccinimidyl) suberate. Biochemistry 1989; 28: 8326-8336
• 8 Booth WJ, Andrews RK, Castaldi PA, Berndt MC. The interaction of von Willebrand factor and the platelet glycoprotein Ib – IX complex. Platelets 1990; 1: 169-176
• 9 Pareti FI, Fujimura Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM. Isolation and characterization of a collagen binding domain in human von Willebrand factor. J Biol Chem 1986; 261: 15310-15315
• 10 Christophe O, Obert B, Meyer D, Girma JP. Localization within von Willebrand factor of a binding site for sulfatides comprising AA 569 to 584. Thromb Haemostas 1991; 65: 421 (Abstract 797)
• 11 Denis C, Baruch D, Christophe O, Aizenberg N, Girma JP, Meyer D. Localization of an extracellular matrix (ECM) binding site on von Willebrand factor (vWF) between amino acids (aa) 449 and 728. Thromb Haemostas 1991; 65: 422 (Abstract 798)
• 12 Kalafatis M, Girma JP, Dupin S, Takahashi Y, Meyer D. The N terminal monomeric 34 kDa fragment (residues 1-298) of human von Willebrand factor contains two distinct binding domains one for FVIII and one for heparin. Thromb Haemostas 1989; 62: 217 (Abstract 670)
• 13 Ruggeri ZM, Zimmerman TS. Classification of von Willebrand disease. J Clin Lab Anal 1987; 1: 353-362
• 14 Berkowitz SD, Ruggeri ZM, Zimmerman TS. Von Willebrand’s disease. Coagulation and bleeding disorders. The role of factor VIII and von Willebrand factor. New York: Marcel Dekker; 1989. 9 215-259
• 15 Mazurier C, Parquet-Gernez A, Samor B, Goudemand M, Montreuil J. Etude de l’antigène lié au facteur VIII (FVIII R: Ag). Purification par chromatographie d’immunoaffinité. CR Acad Sci 1979; 288: 1431-1434
• 16 Jorieux S, De Romeuf C, Samor B, Goudemand M, Mazurier C. Characterization of a monoclonal antibody to von Willebrand factor as a potent inhibition of ristocetin-mediated platelet interaction and platelet adhesion. Thromb Haemostas 1987; 57: 278-282
• 17 Mazurier C, Parquet-Gernez A, Goudemand M. Dosage de l’antigène lié au facteur VIII par la technique ELISA. Intérêt dans l’étude de la maladie de Willebrand. Path Biol 1977; 25 (Suppl. 00) 18-24
• 18 Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis. Thromb Haemostas 1986; 55: 61-64
• 19 Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rosers M, Bolhuis PA. Adhesion of platelets to human artery subendothelium: Effect of factor VIII – von Willebrand factor of various multimeric composition. Blood 1984; 63: 128-139
• 20 Schullek J, Jordan J, Montgomery RR. Interaction of von Willebrand factor with human platelets in the plasma milieu. J Clin Invest 1984; 73: 421-428
• 21 Lopez-Fernandez MF, Lopez-Berges C, Corral M, Garcia-Talavera JR, Lopez-Borrasca A, Battle J. Assessment of multimeric structure and ristocetin induced binding to platelets of von Willebrand factor present in cryoprecipitate and different factor VIII concentrates. Vox Sang 1987; 52: 15-19
• 22 Kroner PA, Kluessendorf HL, Scott JP, Montgomery RR. A Pro ⁵⁷⁴ → Leu substitution in von Willebrand factor enhances the binding of expressed protein to platelets and is linked to type IIB von Willebrand’s disease. Thromb Haemostas 1991; 65: 763 (Abstract 330)
• 23 Ware J, Dent JA, Azuma H, Sugimoto M, Kyrle PA, Yoshioka A, Ruggeri ZM. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib – IX receptor. Proc Natl Acad Sci 1991; 88: 2946-2950
• 24 Randi AM, Jorieux S, Tuley EA, Mazurier C, Sadler JE. Recombinant von Willebrand disease mutation affects binding to glycoprotein-Ib but not to collagen or heparin. J Biol Chem 1992; 267: 21187-21192
• 25 Pietu G, Ribba AS, de Pailette L, Chérel G, Lavergne JM, Bahnak BR, Meyer D. Molecular study of von Willebrand disease: identification of potential mutations in patients with type IIA and type IIB. Blood Coagulation Fibrinolysis 1992; 3: 415-421
• 26 Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets. Blood 1992; 79: 2048-2055
• 27 Lyons SE, Bruck ME, Walter BowieEJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-4430
• 28 Gaucher C, Parquet-Gernez A, Hanss M, Horellou MH, Goudemand M, Mazurier C. Potential new mutations in french families with type IIA and IIB von Willebrand’s disease (vWD). XX International Congress of the World Federation of Haemophilia. 1992; 176 (Abstract 347)
• 29 Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a human binding domain peptide of von Willebrand factor. J Biol Chem 1992; 267: 8857-8862